All Stories

  1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection
  2. Statistical analysis plan for the biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2) study: An international randomised controlled multicentre trial
  3. Effect of a single small volume fluid bolus with balanced or un-balanced fluids on chloride and acid–base status: a prospective randomized pilot study (the FLURES-trial)
  4. Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
  5. Regional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis
  6. Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
  7. Immunological sub-phenotypes and response to Convalescent Plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial.
  8. CCL14 Predicts Oliguria and Dialysis Requirement in Patients with Moderate to Severe Acute Kidney Injury
  9. Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
  10. Lack of association between HLA and asymptomatic SARS-CoV-2 infection
  11. A global perspective on acute kidney injury after major surgery: much needed insights and sobering results
  12. Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients
  13. Initiation of continuous renal replacement therapy versus intermittent hemodialysis in critically ill patients with severe acute kidney injury: a secondary analysis of STARRT-AKI trial
  14. Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU
  15. Performance of urinary C–C motif chemokine ligand 14 for the prediction of persistent acute kidney injury: a systematic review and meta-analysis
  16. Ferroptosis and pyroptosis signatures in critical COVID-19 patients
  17. The effects of differing anticoagulant regimes on blood quality after cell salvage in coronary artery bypass grafting (CABG): a pilot study
  18. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
  19. Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy: a narrative review
  20. Potential of Urine Biomarkers CHI3L1, NGAL, TIMP-2, IGFBP7, and Combinations as Complementary Diagnostic Tools for Acute Kidney Injury after Pediatric Cardiac Surgery: A Prospective Cohort Study
  21. Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury
  22. Correction: Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial
  23. Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial
  24. Acute and chronic cardiovascular consequences of acute kidney injury: a systematic review and meta-analysis.
  25. Adult essential extracorporeal membrane oxygenation (ECMO) skills for use in an e-learning program for ICU physicians, nurses and perfusionists: a consensus by a modified Delphi questionnaire
  26. Characterising acute kidney injury: The complementary roles of biomarkers of renal stress and renal function
  27. Impact of mean perfusion pressure and vasoactive drugs on occurrence and reversal of cardiac surgery-associate acute kidney injury: A cohort study
  28. Predictive value of the renal resistive index in the immediate postoperative period after kidney transplantation on short- and long-term graft and patient outcomes
  29. Impact of tight blood glucose control within normal fasting ranges with insulin titration prescribed by the Leuven algorithm in adult critically ill patients: the TGC-fast randomized controlled trial
  30. Impact of tight blood glucose control within normal fasting ranges with insulin titration prescribed by the Leuven algorithm in adult critically ill patients: the TGC-fast randomized controlled trial
  31. Acute kidney injury in critical COVID-19: a multicenter cohort analysis in seven large hospitals in Belgium
  32. Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’
  33. Targeting ferroptosis protects against experimental (multi)organ dysfunction and death
  34. Prediction of cardiac surgery associated - acute kidney injury (CSA-AKI) by healthcare professionals and urine cell cycle arrest AKI biomarkers [TIMP-2]*[IGFBP7]: A single center prospective study (the PREDICTAKI trial)
  35. Illness cognitions and health-related quality of life in liver transplant patients related to length of stay, comorbidities and complications
  36. The AKI care bundle: all bundle components are created equal—are they?
  37. Augmented renal clearance in critically ill COVID-19 patients: Forewarned is forearmed
  38. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
  39. The Prognostic Value of Cardiac Biomarkers and Echocardiography in Critical COVID-19
  40. Impact of AKI care bundles on kidney and patient outcomes in hospitalized patients: a systematic review and meta-analysis
  41. Patients with Severe Lactic Acidosis in the Intensive Care Unit: A Retrospective Study of Contributing Factors and Impact of Renal Replacement Therapy
  42. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
  43. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
  44. Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
  45. Integration of Equipoise into Eligibility Criteria in the STARRT-AKI Trial
  46. Acute kidney injury in the critically ill: an updated review on pathophysiology and management
  47. The importance of the urinary output criterion for the detection and prognostic meaning of AKI
  48. When should we start renal-replacement therapy in critically ill patients with acute kidney injury: do we finally have the answer?
  49. Prevention of Cardiac Surgery–Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial
  50. Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial
  51. Targeting ferroptosis protects against multiorgan dysfunction and death.
  52. Temporal changes in the epidemiology, management, and outcome from acute respiratory distress syndrome in European intensive care units: a comparison of two large cohorts
  53. What every Intensivist should know about COVID-19 associated acute kidney injury
  54. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
  55. Publisher Correction: COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  56. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  57. Acute cardiorenal syndrome in acute heart failure: focus on renal replacement therapy
  58. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
  59. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
  60. Comparison of predication of Acute Kidney Injury after cardiac surgery by health care providers versus the biomarker [TIMP-2]*[IGFBP7] and scoring systems. Protocol for a prospective single center observational study (PREDICTAKI)
  61. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury
  62. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans
  63. Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort
  64. A Multinational Observational Study Exploring Adherence With the Kidney Disease
  65. Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre): protocol for a multicentre, observational study followed by randomised controlled feasibili...
  66. Focus on metabolism, acute kidney injury and its influence on systemic organs
  67. Protocol and statistical analysis plan for the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney Injury—REVERSE‐AKI randomized controlled pilot trial
  68. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study
  69. Net Ultrafiltration Prescription and Practice Among Critically Ill Patients Receiving Renal Replacement Therapy
  70. Lung–kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup
  71. Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section
  72. Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion
  73. Evaluation of the quality of the communication and emotional support during the donation procedure: The use of the donor family questionnaire (DFQ)
  74. Contrast-associated acute kidney injury: does it really exist, and if so, what to do about it?
  75. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy
  76. Cytokine removal in human septic shock: Where are we and where are we going?
  77. Adherence to guidelines for the management of donors after brain death
  78. Model for end-stage liver disease score and hemodynamic instability as a predictor of poor outcome in early transjugular intrahepatic portosystemic shunt treatment for acute variceal hemorrhage
  79. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury
  80. Plasma neutrophil gelatinase-associated lipocalin (NGAL) for timing of initiation of renal replacement therapy for acute kidney injury?
  81. Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids
  82. Global epidemiology and outcomes of acute kidney injury
  83. Update on Perioperative Acute Kidney Injury
  84. Development of key interventions and quality indicators for the management of an adult potential donor after brain death: a RAND modified Delphi approach
  85. Angiotensin inhibition in patients with acute kidney injury: Dr. Jekyll or Mr. Hyde?
  86. Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults
  87. Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP)
  88. Low flow extracorporeal CO2 removal in ARDS patients: a prospective short-term crossover pilot study
  89. Brief Orals
  90. Epidemiology of cardiac surgery-associated acute kidney injury
  91. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017
  92. A nephrologist should be consulted in all cases of acute kidney injury in the ICU: No
  93. Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference
  94. Diagnostic work-up and specific causes of acute kidney injury
  95. Recovery after Acute Kidney Injury
  96. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury
  97. Diagnosis of cardiac surgery-associated acute kidney injury: differential roles of creatinine, chitinase 3-like protein 1 and neutrophil gelatinase-associated lipocalin: a prospective cohort study
  98. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup
  99. The intensive care medicine agenda on acute kidney injury
  100. Assessment of the Optimal Operating Parameters during Extracorporeal CO2 Removal with the Abylcap® System
  101. Diagnosis of cardiac surgery-associated acute kidney injury from functional to damage biomarkers
  102. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications
  103. Nomenclature for renal replacement therapy in acute kidney injury: basic principles
  104. Defining the characteristics and expectations of fluid bolus therapy: A worldwide perspective
  105. Understanding oliguria in the critically ill
  106. Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study
  107. Recommendations for further improvement of the deceased organ donation process in Belgium
  108. Care pathways for organ donation after brain death: guidance from available literature?
  109. Zero deaths from AKI by 2025: focus on awareness and therapy
  110. The perceived quality of interprofessional teamwork in an intensive care unit: A single centre intervention study
  111. Applications for Detection of Acute Kidney Injury Using Electronic Medical Records and Clinical Information Systems: Workgroup Statements from the 15th ADQI Consensus Conference
  112. Impact of Electronic-Alerting of Acute Kidney Injury: Workgroup Statements from the 15th ADQI Consensus Conference
  113. Urinary chitinase 3-like protein 1 for early diagnosis of acute kidney injury: a prospective cohort study in adult critically ill patients
  114. How to Solve the Underestimated Problem of Overestimated Sodium Results in the Hypoproteinemic Patient
  115. Treating Acute Kidney Injury. One Less Weapon in the Armamentarium?
  116. Precision Fluid Management in Continuous Renal Replacement Therapy
  117. Acute Kidney Injury in Cardiorenal Syndrome Type 1 Patients: A Systematic Review and Meta-Analysis
  118. Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery
  119. Faculty of 1000 evaluation for The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock.
  120. Early diagnosis of AKI in the ICU: urinary chitinase 3-like protein 1 as a novel renal troponin
  121. Relative Low Flow Extra Corporeal Co2-Removal in Ards Patients: A Pilot Study
  122. Long-term quality of life in critically ill patients with acute kidney injury treated with renal replacement therapy: a matched cohort study
  123. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study
  124. Fluid challenges in intensive care: the FENICE study
  125. Influence of severity of illness on neutrophil gelatinase-associated lipocalin performance as a marker of acute kidney injury: a prospective cohort study of patients with sepsis
  126. Comparison of different equations to assess glomerular filtration in critically ill patients
  127. Variation in Risk and Mortality of Acute Kidney Injury in Critically Ill Patients: A Multicenter Study
  128. Tissue Inhibitor Metalloproteinase-2 (TIMP-2)*IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI
  129. Contrast-associated AKI in the critically ill
  130. Acute kidney injury survivors should have long-term follow-up
  131. Belgian Modified Classification of Maastricht for Donors After Circulatory Death
  132. Four phases of intravenous fluid therapy: a conceptual model †
  133. The 12th consensus conference of the Acute Dialysis Quality Initiative (ADQI XII) †
  134. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers
  135. AKI in early sepsis is a continuum from transient AKI without tubular damage over transient AKI with minor tubular damage to intrinsic AKI with severe tubular damage
  136. A Multiscale Entropy-Based Tool for Scoring Severity of Systemic Inflammation*
  137. Severe lactic acidosis in critically ill patients with acute kidney injury treated with renal replacement therapy
  138. How has urinary proteomics contributed to the discovery of early biomarkers of acute kidney injury?
  139. CLINICAL ACUTE KIDNEY INJURY 1
  140. “Piece” of mind: End of life in the intensive care unit Statement of the Belgian Society of Intensive Care Medicine
  141. What’s new in the controversy on the renal/tissue toxicity of starch solutions?
  142. Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)
  143. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
  144. Implementing the Kidney Disease
  145. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy
  146. A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*
  147. Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion
  148. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
  149. Cardiorenal Syndrome Type 3: Pathophysiologic and Epidemiologic Considerations
  150. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
  151. Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)
  152. Urinary output and fractional excretion of sodium and urea as indicators of transient versus intrinsic acute kidney injury during early sepsis
  153. Urinary chitinase 3-like 1, a novel biomarker for acute kidney injury in adult cardiac intensive care patients: a pilot study
  154. ESICM 2012 MONDAY SESSIONS 15 October, 2012
  155. Mortality after surgery in Europe: a 7 day cohort study
  156. Renal Physiology in the Critically Ill Obese Patient
  157. Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure
  158. Impact of real-time electronic alerting of acute kidney injury on therapeutic intervention and progression of RIFLE class*
  159. Recommendations for the Management of Crush Victims in Mass Disasters
  160. Section I: Definitions and Basic Concepts
  161. Epidemiology of contrast-associated acute kidney injury in ICU patients: reply to Valette and du Cheyron
  162. Prerenal Azotemia
  163. AKI patients have worse long-term outcomes, especially in the immediate post-ICU period
  164. Contrast Nephropathy
  165. Epidemiology of contrast-associated acute kidney injury in ICU patients: a retrospective cohort analysis
  166. In Reply to ‘Intra-abdominal Pressure Can Be Estimated Inexpensively by the Sagittal Abdominal Diameter'
  167. Serum urea concentration is probably not related to outcome in ICU patients with AKI and renal replacement therapy
  168. Clinical review: Use of renal replacement therapies in special groups of ICU patients
  169. Intra-abdominal Hypertension and Abdominal Compartment Syndrome
  170. Clinical Consequences of Acute Kidney Injury
  171. Morbidity and Mortality of Bloodstream Infections in Patients With Severe Burn Injury
  172. Defining acute kidney injury: playing hide-and-seek with the unknown man?
  173. Application of the RIFLE criteria in patients with crush-related acute kidney injury after mass disasters
  174. Outcome of acute kidney injury in severe burns: a systematic review and meta-analysis
  175. AKI severity class doesn't tell all: the case for transient AKI
  176. Antimicrobial prophylaxis in liver transplant patients – a multicenter survey endorsed by the European Liver and Intestine Transplant Association
  177. A comparison of three methods to estimate baseline creatinine for RIFLE classification
  178. Pro/con debate: Continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?
  179. ARDS of Early or Late Onset
  180. Acute Kidney Injury in Critically Ill Patients with Cancer
  181. Abdominal decompression for intra-abdominal hypertension after simultaneous pancreas-kidney transplantation
  182. Epidemiology of Acute Kidney Injury
  183. Modern Classification of Acute Kidney Injury
  184. Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury
  185. Severe burn injury in europe: a systematic review of the incidence, etiology, morbidity, and mortality
  186. Thrombocytopenia and outcome in critically ill patients with bloodstream infection
  187. Intensive vs conventional blood glucose control in critically ill patients
  188. How to remove accumulated iodine in burn-injured patients
  189. Prerenal Acute Kidney Failure
  190. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis
  191. Epidemiology of infection in critically ill patients with acute renal failure
  192. Enterobacteriaceaebacteremia after liver transplantation
  193. Intensive insulin therapy: The swinging pendulum of evidence*
  194. The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury
  195. Development and validation of a model for prediction of mortality in patients with acute burn injury
  196. Acute kidney injury in the intensive care unit: It’s the gene, stupid!*
  197. The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI
  198. The value of procalcitonin to diagnose infection in critically ill patient: caveat emptor!
  199. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial
  200. Impact of local circumstances on outcome of renal casualties in major disasters
  201. Variation in critical care services across North America and Western Europe*
  202. Blood Stream Infections of Abdominal Origin in the Intensive Care Unit: Characteristics and Determinants of Death
  203. Epidemiology of acute kidney injury: How big is the problem?
  204. Timing of Initiation and Discontinuation of Renal Replacement Therapy in AKI: Unanswered Key Questions
  205. Trends in mortality in coronary artery bypass graft patients with acute renal failure
  206. Transvesical intra-abdominal pressure measurement using minimal instillation volumes: how low can we go?
  207. Development of a Clinical Research Agenda for Acute Kidney Injury Using an International, Interdisciplinary, Three-Step Modified Delphi Process
  208. Acute kidney injury in burns: a story of volume and inflammation
  209. Acute kidney injury: Epidemiology and assessment
  210. Service-oriented Subscription Management of Medical Decision Data in the Intensive Care Unit
  211. The Diagnosis of Relative Adrenal Insufficiency: The Long and Winding Road…
  212. Dynamics of C-reactive protein and white blood cell count in critically ill patients with nosocomial Gram positive vs. Gram negative bacteremia: a historical cohort study
  213. Health Implications of Antimicrobial Resistance for Patients With Acute Kidney Injury and Bloodstream Infection
  214. The effect of neuromuscular blockers in patients with intra-abdominal hypertension
  215. Relative adrenal insufficiency in patients with severe acute pancreatitis
  216. Semicontinuous intra-abdominal pressure measurement using an intragastric Compliance catheter
  217. Extrapancreatic Inflammation on Abdominal Computed Tomography as an Early Predictor of Disease Severity in Acute Pancreatitis
  218. The future of surgical critical care: A European perspective
  219. Earthquakes and crush syndrome casualties: Lessons learned from the Kashmir disaster
  220. A novel approach for prediction of tacrolimus blood concentration in liver transplantation patients in the intensive care unit through support vector regression
  221. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
  222. Incidence, Classification, and Outcomes of Acute Kidney Injury
  223. ACUTE KIDNEY INJURY 2007
  224. ACUTE KIDNEY INJURY, LENGTH OF STAY, AND COSTS IN PATIENTS HOSPITALIZED IN THE INTENSIVE CARE UNIT
  225. EPIDEMIOLOGY OF AKI IN THE ICU
  226. IMPLEMENTATION OF A REAL-TIME ELECTRONIC ALERT BASED ON THE RIFLE CRITERIA FOR ACUTE KIDNEY INJURY IN ICU PATIENTS
  227. LONG-TERM OUTCOME AFTER ACUTE KIDNEY INJURY IN CRITICALLY-ILL PATIENTS
  228. SEVERE INFECTION, SEPSIS AND ACUTE KIDNEY INJURY
  229. Acute kidney injury: epidemiology and diagnostic criteria
  230. RIFLE criteria provide robust assessment of kidney dysfunction and correlate with hospital mortality*
  231. Effect of fluconazole consumption on long-term trends in candidal ecology
  232. Current pharmacotherapeutic recommendations for acute pancreatitis
  233. Saline volume in transvesical intra-abdominal pressure measurement: enough is enough
  234. Clinical and Economic Outcomes in Critically Ill Patients with Nosocomial Catheter-Related Bloodstream Infections
  235. Outcome and changes over time in survival following severe burns from 1985 to 2004
  236. Would Patients with More Subtle Signs of Coagulopathy Have Benefited from Treatment with Activated Protein C?
  237. Colonization Status and Appropriate Antibiotic Therapy for Nosocomial Bacteremia Caused by Antibiotic-Resistant Gram-Negative Bacteria in an Intensive Care Unit
  238. Influence of Matching for Exposure Time on Estimates of Attributable Mortality Caused by Nosocomial Bacteremia in Critically Ill Patients
  239. Physiologic Consequences of Acute Renal Failure on the Critically Ill
  240. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine
  241. Fluid vs. air for semicontinuous intra-abdominal pressure measurements using a compliance catheter
  242. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies
  243. Phenytoin intoxication in critically ill patients
  244. Acute Effects of Upright Position on Gas Exchange in Patients With Acute Respiratory Distress Syndrome
  245. Emergence of Antibiotic Resistance in Infected Pancreatic Necrosis
  246. Reflections on the definition, classification, and diagnostic evaluation of acute renal failure
  247. The assumed problem of air bubbles in the tubing during intra-abdominal pressure measurement
  248. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study
  249. Effect of Nosocomial Bloodstream Infection on the Outcome of Critically Ill Patients with Acute Renal Failure Treated with Renal Replacement Therapy
  250. Absence of Excess Mortality in Critically Ill Patients With Nosocomial Escherichia coli Bacteremia
  251. Adrenal Insufficiency in Severe Acute Pancreatitis
  252. Estimates of attributable mortality of systemic candida infection in the ICU
  253. Acute Renal Failure in Patients with Sepsis in a Surgical ICU: Predictive Factors, Incidence, Comorbidity, and Outcome
  254. Is MRSA More Pathogenic in Critically Ill Patients?—Reply
  255. The Effect of Tube Thoracostomy on Oxygenation in ICU Patients
  256. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication*
  257. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa
  258. No early respiratory benefit with CVVHDF in patients with acute renal failure and acute lung injury
  259. Outcome and Attributable Mortality in Critically Ill Patients With Bacteremia Involving Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus
  260. Effects of nosocomial candidemia on outcomes of critically ill patients
  261. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults?
  262. Clinical Characteristics of Septic Patients Developing Acute Renal Failure (ARF)
  263. Significant increase of activated partial thromboplastin time by heparinization of the radial artery catheter flush solution with a closed arterial catheter system
  264. Carsin H, et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. Burns 2000;26:379–387
  265. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata
  266. Staphylococcal septicaemia in burns
  267. Ozumba UC, Jiburum BC. Bacteriology of burn wounds in Enugu, Nigeria. Burns 2000; 26(2): 178–80
  268. Modulation of liver graft hemodynamics by partial ablation of the splenic circuit: a way to increase hepatic artery flow?
  269. Inadequate Proof of Adverse Outcome Due to the Use of Fluconazole in Critically Ill Patients
  270. Antibiotic Resistance and Exposure to Different Generation Cephalosporins
  271. Tracheal Colonization in Pneumonia
  272. Biocompatibility and acute renal failure
  273. Use of continuous bispectral EEG monitoring to assess depth of sedation in ICU patients
  274. Management of Candidal Thrombophlebitis of the Central Veins: Case Report and Review
  275. The Organization of the European Renal Disaster Relief Task Force
  276. Different Types of Dialyzer Membranes: Does the Bio(in)compatibility Matter in the Treatment of ARF?
  277. Pathophysiology, Causes, and Prognosis of Acute Renal Failure in the Elderly
  278. Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol
  279. Definition, Classification, and Epidemiology of Acute Kidney Disease